{"result": "(\"entity\"<|>NUTRICIÓN PARENTERAL TOTAL<|>EVENT<|>Nutrición parenteral total (NPT) is a medical treatment used when enteral nutrition is contraindicated or not tolerated, involving the intravenous administration of nutrients.)\n##\n(\"entity\"<|>FÍSTULAS ENTEROCUTÁNEAS<|>EVENT<|>Fístulas enterocutáneas are abnormal connections between the intestine and the skin, which can be treated with NPT if certain conditions are met.)\n##\n(\"entity\"<|>SÍNDROME DE INTESTINO CORTO<|>EVENT<|>Síndrome de intestino corto is a condition that can require NPT, particularly when there is a significant loss of intestinal length.)\n##\n(\"entity\"<|>SÍNDROME SUBOCLUSIVO<|>EVENT<|>Síndrome suboclusivo is a condition that may be managed with NPT and digestive aspiration to avoid surgery.)\n##\n(\"entity\"<|>PROBIÓTICOS<|>EVENT<|>Probióticos are live microorganisms that provide health benefits when consumed, and they can influence gut microbiota.)\n##\n(\"entity\"<|>Lactobacilli<|>EVENT<|>Lactobacilli are a type of probiotic bacteria that can have beneficial effects on gut health.)\n##\n(\"entity\"<|>Bifidobacterium<|>EVENT<|>Bifidobacterium is another type of probiotic that contributes to gut health and is included in probiotic treatments.)\n##\n(\"entity\"<|>Escherichia coli Nissle 1917<|>EVENT<|>Escherichia coli Nissle 1917 is a specific strain of probiotic bacteria studied for its health benefits in the gastrointestinal tract.)\n##\n(\"relationship\"<|>NUTRICIÓN PARENTERAL TOTAL<|>FÍSTULAS ENTEROCUTÁNEAS<|>NPT is indicated for the treatment of enterocutaneous fistulas under certain conditions<|>7)\n##\n(\"relationship\"<|>NUTRICIÓN PARENTERAL TOTAL<|>SÍNDROME DE INTESTINO CORTO<|>NPT is used in patients with short bowel syndrome to maintain nutrition<|>7)\n##\n(\"relationship\"<|>NUTRICIÓN PARENTERAL TOTAL<|>SÍNDROME SUBOCLUSIVO<|>NPT can help manage symptoms of subocclusive syndrome and avoid surgery<|>6)\n##\n(\"relationship\"<|>PROBIÓTICOS<|>Lactobacilli<|>Lactobacilli are a type of probiotic that provides health benefits in the gut<|>8)\n##\n(\"relationship\"<|>PROBIÓTICOS<|>Bifidobacterium<|>Bifidobacterium is another type of probiotic that contributes to gut health<|>8)\n##\n(\"relationship\"<|>PROBIÓTICOS<|>Escherichia coli Nissle 1917<|>Escherichia coli Nissle 1917 is a specific strain of probiotic studied for its benefits<|>8)\n<|COMPLETE|>", "input": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: ía por vía endoscópica); y c) sobre todo en el tratamiento del retraso de crecimiento de niños y adolescentes con EC49.\n\nLas contraindicaciones absolutas del uso de NE son la presencia de fístulas yeyunales de alto flujo, obstrucción intestinal completa, síndrome de intestino corto severo con elevado número de deposiciones o con una longitud inferior a 100 cm, hemorragia gastrointestinal grave o masiva, perforación intestinal, sepsis intrabdominal o megacolon tóxico.\n\n## 6.2. Nutrición parenteral total (NPT)\n\nSus riesgos y su coste no justifican la utilización de forma general, por lo que su indicación es para aquellas situaciones en que la nutrición enteral está contraindicada o no se tolera, ya que el reposo intestinal no mejora el curso de la enfermedad.\n\nExiste un único estudio que compara NE frente a NP en pacientes con CU (se encuentran en tratamiento con dosis plenas de corticoesteroides) en sus resultados no se observaron diferencias en la evolución de la enfermedad, en el número de fracasos a corticoides ni en mayor frecuencia de precisar cirugía. Por otra parte el número de infecciones del postoperatorio fue superior en los tratados con NP45. Las indicaciones principales de NP en la EII son:\n\n### 6.2.1. Fístulas enterocutáneas de alto débito\n\nLas originadas por EC tienen mejor pronóstico que las originadas por una cirugía previa21. La NPT favorece el cierre de las mismas siempre que no haya un obstáculo distal, exista continuidad anatómica del tubo digestivo y se drenen las colecciones purulentas. Se cierran el 44% de fístulas simples con NPT21.\n\n### 6.2.2. Síndrome de intestino corto\n\nEn una fase inicial se puede asociar a NE (deben existir al menos 100 cm), hasta lograr la readaptación del tubo digestivo. Se debe mantener si persiste un número elevado de deposiciones o de volumen. Son la principal causa de NPT domiciliaria, y se debería comenzar antes de la cirugía para prevenir las pérdidas proteicas asociadas a la cirugía21.\n\n### 6.2.3. Síndrome suboclusivo\n\nLa NPT y la aspiración digestiva pueden resolver el cuadro evitando la cirugía.\n\nLas complicaciones asociadas a su técnica son: cateterización de vena central, sepsis, trombosis venosa, neumotórax y daño del conducto linfático. Las complicaciones asociadas a su uso incluyen: intoxicación por manganeso, déficit de cobre, encefalopatía de Wernicke, beri-beri. Precisan un control estrecho de electrolitos, vitaminas y otros elementos, unas condiciones higiénicas apropiadas, una educación y un personal a su cargo entrenado.\n\nEn la EC es efectiva como tratamiento primario en enfermedad refractaria o con alta recurrencia y en la CU no se considera como tratamiento primario, aunque se ha demostrado una remisión del 30%50.\n\nEl tratamiento en pacientes desnutridos que necesitan cirugía a corto plazo disminuye las complicaciones postoperatorias y el área resecada, aunque en ningún caso se ha demorar una intervención urgente para mejorar el estado nutricional del paciente.\n\n## 6.3. Probióticos. Prebióticos y nutrientes específicos\n\n### 6.3.1. Probióticos\n\nSon microorganismos vivos que sobreviven al paso por el tracto gastrointestinal y tienen efectos beneficiosos en el huésped, incluyen: Lactobacilli, Bifidobacterium, cocos gram positivos, enterococos, levaduras (Saccharomyces boulardii) y hongos (Aspergillus orizae).\n---\n492     BLOQUE: NUTRICIÓN EN PATOLOGÍA DEL TUBO DIGESTIVO\n\nRecientemente se ha cuestionado la viabilidad de estos microorganismos en el tubo digestivo, aunque en numerosos estudios se ha demostrado el cambio en el perfil microbiano y actividad metabólica de las heces, así como su resistencia a la acidez gástrica y su actividad intestinal33. Para conseguir resultados no es necesaria la colonización, deben ser ingeridos continuamente, ya que no se adhieren ni multiplican. Otro beneficio asociado es el que se desprende del descenso de actividad bacteriana de beta-glucoronidasa y beta-glucosidasa, implicadas en la circulación enterohepática de sustancias tóxicas y carcinogénicas33.\n\nEl mecanismo de acción (tabla 3) pasa principalmente por la búsqueda del equilibrio entre microbiota comensal y patogénica. De todas las bacterias estudiadas, únicamente Escherichia coli Nissle 1917, Saccharomyces boulardii y VSL-3 (una mezcla de 8 bacterias: Lacid\n######################\nOutput:", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": null}